Toxina botulínica A para o trismo no tétano cefálico by Andrade, Luiz Augusto Franco de & Brucki, Sonia Maria D.
BOTULINUM TOXIN A FOR TRISMUS IN CEPHALIC TETANUS 
LUIZAUGUSTOF.ANDRADE*, SOMA MARIA D.BRUCKI** 
SUMMARY - Cephalic tetanus is a localized form of tetanus. As in generalized forms , trismus is a prominent 
feature of the disease, leading to considerable difficulty in feeding, swallowing of the saliva and mouth hygiene. 
These difficulties often precede respiratory problems and aspiration bronchopneumonia is a frequent life-
threatening complication. Muscle relaxants other than curare drugs may show a limited benefit for relieving 
trismus. Tetanospasmin, the tetanic neurotoxin, and botulinum toxin share many similarities, having a closely 
related chemical structure, an origin from related microorganisms (Clostridium tetani and Clostridium botulinum, 
respectively), and presumably, the same mechanisms of action in the neuron. The difference between the two 
lies in their peculiar neurospecificity, acting in different neurons. Injection of minute doses of botulinum toxin 
in the muscles involved in focal dystonias or other localized spastic disorders have proved to be very effective in 
these conditions. We describe the use of botulinum toxin A in the successful treatment of trismus in a patient 
suffering from cephalic tetanus. We believe that this form of treatment may be of value in lowering the risk of 
pulmonary complications in tetanic patients. 
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Toxina botulínica A para o trismo no tétano cefálico 
RESUMO - O tétano cefálico é uma forma localizada de tétano. Da mesma maneira que nas formas generalizadas, 
o trismo é componente clínico proeminente, que leva a grande dificuldade na alimentação, na deglutição da 
saliva e para a higiene da boca. Essas dificuldades freqüentemente precedem os problemas respiratórios e as 
pneumonias aspirativas, que se constituem em complicações que ameaçam a vida dos pacientes. Drogas relaxantes 
musculares de outro tipo que as drogas curarizantes trazem pouco benefício para o trismo. A neurotoxina 
tetânica (tetanospasmin) e a toxina botulínica compartilham muitas semelhanças, como estrutura química simile, 
origem de microorganismos relacionados (Clostridium tetani e Clostridium botulinum, respectivamente) e, 
presumivelmente, os mesmos mecanismos de ação no neurônio. A diferença entre as duas reside na sua peculiar 
neuroespecificidade, atuando em diferentes neurônios. Injeção de doses reduzidas da toxina botulínica em 
músculos envolvidos em distonias focais ou outras desordens com espasticidade muscular localizada tem se 
mostrado eficaz em abolir as contrações. Descrevemos o uso da toxina botulínica A com sucesso no tratamento 
do trismo num paciente sofrendo de tétano cefálico. Acreditamos que esta forma de tratamento possa ser de 
valor no sentido de diminuir o risco de complicações pulmonares nos pacientes com tétano. 
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Cephalic tetanus is an unusual, localized form of tetanus. The disease is caused by the action 
of a neurotoxin, tetanospasmin (TS), which is produced by Clostridium tetani. Although a rare 
disease in civilized countries, tetanus still remains as a concern in developing and under civilized 
countries, owing to the great number of cases. Neonates and unimmunized or inadequately immunized 
children and young adults are more prone to the disease3 8. Most cases present as generalized tetanus. 
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TS entries the nervous system predominantly at the myoneural junctions of the alpha motor neurons 
and an axonal retrograde transport carries the neurotoxin to the central nervous system2. Three 
different levels may be affected by TS: motor control cells in the brainstem or in the spinal cord, 
autonomic cells in different parts of the autonomic system and the neuromuscular junction. Presynaptic 
inhibitory cells, utilizing either glycine or GABA as inhibitory neurotransmitters, in the spinal cord 
and brainstem are target cells to TS. More details on the pathophysiology, management and prophylaxis 
of tetanus may be found in a recent review by Bleck1. Despite considerable improvement in the 
management of respiratory complications, with more effective muscle relaxants, sophisticated 
mechanical respiratory devices, new antibiotics and better intensive care, fatal outcomes are still 
seen in many cases. Bronchopneumonia, mainly due to aspiration is highly prevalent. Trismus may 
be a particular contributing mechanical factor that enhances aspiration, in addition to swallowing 
difficulty. Curare drugs have been considered the only effective drugs for abolishing the spasms. 
The botulinum toxin (botox), another potent neurotoxin, produced by the Clostridium 
botulinum is very similar to TS. Its site of action is predominantly the synaptic terminal of the 
cholinergic lower motor neuron. TS and botox share a very similar chemical structure, the same 
mechanisms of action, strong potency but different neurospecifícity. Opposed to TS, botox causes 
flaccid paralysis due to neuroexocytosis block at the neuromuscular junction6. Localized injections 
of minute doses of botulinum toxin A has been successfully used for the treatment of different 
conditions where muscular spasms predominate, as in focal dystonias (blepharospasm, cervical, 
oro-mandibular and laryngeal dystonias, writers cramp), hemifacial spasm and other similar conditions. 
In a recent case of cephalic tetanus we had the opportunity of treating the trismus with botulinum 
toxin A, thus improving the patient's respiratory distress, allowing proper mouth hygiene and secretion 
aspiration, as well as returning him to a much more confortable feeding condition. 
CASE REPORT 
JNS (RG.811551), male, 33 years-old, black, was admitted to Hospital São Paulo on November, 23rd., 
1992. Eight days before, working in a building construction, he had a fall banging his forehead on the ground 
and producing an open wound in his nose bridge. On that same day he was treated, receiving a tetanic antitoxin 
dose and penicillin. We could not obtain further details concerning these medications. He was well until three 
days before admission, when he started having difficulty, soon followed by incapacity to open his mouth and 
swallowing troubles. His previous medical history was unremarkable. In the admission examination an infected 
open wound in the nose bridge was clear. The patient temperature was normal, as well as all other clinical 
parameters. A pronounced trismus was present rendering him unable to open his mouth, with clenched teeth. 
On palpation, the masseter muscles were tense, hypertonic. There were signs of bilateral facial paresis, as seen 
by lid lag on both eyes. Owing to the dysphagia and the great difficulty of swallowing of his own saliva, along 
with the impossibility of opening his mouth, the patient presented respiratory distress and choking. Neck 
movements were difficult, but all other parts of the body could be easily voluntarily moved. No muscle power 
deficits could be found in these other body segments. Except for the cranial and cervical segment the muscle 
tone was normal. The rest of the clinical and neurological examination was entirely normal. The patient was 
transferred to the ICU and received human tetanic immunoglobulin (TIG), 250 U locally in the wound and 4500 
U IM. A high dose penicillin regimen was started, with a daily dose of 24 million units. A nasogastric feeding 
tube was inserted. 
The diagnosis of cephalic tetanus was clearly obvious and, as usual for tetanus, an early tracheostomy 
was performed. He was put under diazepam, in escalating doses, up to 240 mg/day, to control intense muscle 
spasms in his throat and mouth. Few days after being admitted he developed a pneumonia and started receiving 
cyprofloxacin and ceftazidime in proper amounts. On day 15 of his stay at the ICU his clinical condition had 
deteriorated. Although the pneumonia had subsided he was having trouble with the mechanical ventilator, and 
the medical staff was considering utilizing curare drugs on him. All his difficulties and the excessive manipulations 
he had been submitted would drive him to further pulmonary infections. 
At this stage we decided to treat the trismus with botulinum toxin A (botox). Thirty units were injected 
directly into the bulk of the masseter muscle on either side (in two separate sites) and an additional 20 units dose 
was injected in the more anterior part of this muscle (one site), again on either side. 
Three days after the botox injection the patient experienced a subjective improvement of mouth opening, 
although no clear separation of his teeth could be seen. Four days later, he was able to slightly open his mouth, 
with 0.5 cm separation between the upper and lower dental arcades. Ten days after botox he was able to open his 
jaw keeping his teeth 1 cm separated. By then, the feeding nasogastric tube was removed, his mouth hygiene 
could be easily made and swallowing became more effective. When he completed two weeks after botox his 
mouth could open widely. A clear atrophy of both masseter muscles was visible. He was discharged from the 
hospital and followed at the outpatient clinic. One month later he came to a routine visit when his examination 
showed normal findings, but his masseter muscles were still atrophied, although he could open and close normally 
the jaw. 
COMMENTS 
Botulinum toxin and TS are among the more potent neurotoxins existing in nature. The term 
botulinum toxin stands for eight substances belonging to seven different serotypes (A, B, CI, C2, D, 
E, F and G). C2 is a binary toxin. The other seven, known as the botulinum neurotoxins and TS are 
produced by two toxigenic strains of Clostridium, the botulinic and tetanic, respectively. They share 
very similar biochemical structures. Two polypeptide chains, a heavy (100 kDa) and a light (50 kDa) 
with an interchain disulfide bond forms the active neurotoxins5,6. The synthesis and proteolytic 
cleavage is identical to both neurotoxins6. Slight changes in aminoacid sequence make their different 
neurospecific targetting7. TS causes a spastic paralysis due to its blocking action on inhibitory 
interneurons of the brainstem and spinal cord (glycine and GABA neurons). Botox causes a flaccid 
paralysis, blocking neuromuscular transmission presynaptically. Acetylcholine release (exocytosis), 
specifically at the lower motor neuron terminal is blocked by the toxin. Although acting in different 
target neurons, the toxins share the same basic action mechanisms; binding, internalization and 
intracellular poisoning steps are alike. 
When we decided to use botox in order to treat the trismus in our patient, the aim was to 
produce a long lasting "curare-like" localized effect on the masseters. We had some concern in the 
use of botox in a patient suffering from a serious disease produced by a very similar potent neurotoxin. 
To our knowledge no other case of tetanus, in any form, had been treated like this before. As far as 
we could search in the literature, there has been no mention to the simultaneous use of both neurotoxins 
in a single animal. We received an approval of the ethics committee of our institution before making 
the injections. 
There is considerable variation in the natural course of tetanus. Generalized forms carry a 
greater risk for life and the duration of the muscle spasms may vary widely, up to 44 days3, and in our 
institution even longer duration has been seen. Patients requiring respirator treatment may have the 
poorest outcome4. Cephalic tetanus, although being considered a more benign form of the disease 
may, as well, vary greatly in the duration of the trismus and the other manifestations of muscular 
overactivity. In the present case the improvement in jaw opening began few days after the botox 
injection, as it would be expected for a similar treatment in other conditions. In the natural course of 
tetanus an improvement of the muscle spasm in other muscle groups going along with that of the 
masseters would be expected. The rapid and disproportional improvement of the masseters as 
compared to pharyngeal and face muscles in our case made us quite sure that botox had been useful 
for the patient. A further confirmation of the muscular effect was the atrophy which was produced in 
the masseters. We think that botox may be very useful in the treatment of trismus in tetanic patients. 
The possibility of lowering the risk of pneumonia and the improvement in oral hygiene and feeding 
conditions in patients suffering from tetanus are the mainstem of this new application of botulinum 
toxin A. 
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